Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Round 1

Reviewer 1 Report

Saponaro et al. discuss use of adjuvant endocrine therapy (ET) for ER+ breast cancer patients. ET is standard of care for ER+ breast cancer for the first five years, however use of ET beyond five years has mixed results with side effects. Authors perform a retrospective analysis of clinical trials where ET was used beyond five years. Important conclusion from this analysis is to use an individualized multifactorial approach that includes using patient's clinical data along with prognostic/predictive genomic markers that will provide favorable outcome with minimum side effects. Authors discuss these genomic tests in relation to response to ET. Overall, the manuscript is  structured, well-written and provide a summarized analysis of current knowledge and future direction for the field.

Author Response

Dear Dr.

Thanks for your comments

Reviewer 2 Report

This is a very comprehensive, informative and well written review. The manuscript is clearly structured and well understandable.  I have no concerns and would just ask the authors to include the year(s) where the studies were conducted in table 1 and comment on the PALLAS and NATALEE studies in the discussion as these are also using a CDK4/6 inhibitor.

Author Response

Dear Dr.

I' ve included the year  for each trial in tab.1; for trials that have more updates,I added the year relating to data  reported in tab.1.

I added  comments on the PALLAS and NataLEE trial as you required.